Conditions: Arthritis, Rheumatoid
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 56
Healthy volunteers: no

Brief summary:
The purpose of this study is to assess if Abatacept given for six months will prevent rheumatoid arthritis (RA) in patients who are at risk for the development of RA in comparison to placebo. High risk patients are defined as those having a positive laboratory test for anti-cyclic citrullinated peptide (anti-CCP2).

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Abatacept intervention 2: placebo
Intervention descriptions: intervention 1: solution, intravenous injection, monthly, 169 days

weight based:

\<60 kg = 500 mg

60 to 100 kg = 750 mg

\>100 kg = 1 g intervention 2: solution, intravenous injection, 0 mg, monthly, 169 days

Protocol document: